Navigation Links
EU Drug Regulator Highlights Depression Danger of Weight-loss Pill

The European drug regulator EMEA said Thursday it had maintained authorisation of weight-loss pill Acomplia in the European Union, but had ordered it to be withheld from people suffering from depression.

A panel of experts from the US Food and Drug Administration concluded in June that the dieting treatment, which can also be used to treat diabetes, was unsafe because it caused suicidal thoughts as a side-effect.

The maker of the drug, French group Sanofi-Aventis, abandoned attempts to win approval for the drug in the United States as a result.

The European Medicines Agency (EMEA) recommended Thursday that Acomplia, also known as Rimonabant, should not be given to patients with depression or those taking anti-depressants because of the risk of psychiatric side-effects.

The agency said that depression was known as the main side-effect of the drug and this had been signalled at the time of its approval in June 2006.

However, the Agency's Committee for Medicinal Products for Human Use (CHMP) had recommended upgrading the warning about depression.

Sanofi-Aventis, the fourth-biggest drug maker in the world, announced afterwards that it had changed its labelling to take into account the EMEA's comments.

The recommendation from the EMEA will be sent to doctors prescribing drugs in the countries where the drug in being sold.


'"/>




Page: 1

Related medicine news :

1. US Regulator Sees No Link Between Tamiflu And Japan Deaths
2. Tumor Suppressor p53s Contradictory Regulatory System
3. A brush with the U.S. Regulators can cost a fortune
4. Cancer-causing Property Of Teflon Leaves US Regulators Concerned
5. Human Complexity Can Be Attributed To Regulatory Sequence
6. Regulators Object Drug Produced from Genetically Engineered Farm Animals
7. The Lancet Calls For Review Of Regulatory Process Of Drug Trials
8. Medtronic’s Insulin Pump Receives Regulatory Approva
9. Australian Drug Regulators Call for Revamp On The Pharmaceutical Surveillance
10. Drug Regulators Need To Think In Long-Term, Say Charities
11. Regulatory T-cells – Protector or Cause of Diseases
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... ... 2017 , ... Tuesday, March 28, 2017, is the annual American Diabetes Association ... Test to find out if they are at risk for developing Type 2 diabetes. ... evening sky by programming the LAX pylons the color red. Downtown’s U.S. Bank Tower ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... team. Ruel Williamson brings his extensive knowledge of appraisals, property values, ad valorem ... the real estate valuation industry for more than 40 years. , “Ruel is ...
(Date:3/28/2017)... ... 2017 , ... The Thyroid Secret is a specialized 9-part ... program was recently launched on March 1, and Dr. Wentz discussed varied benefits ... Dr. Izabella Wentz is a licensed pharmacist and a foremost thyroid specialist. After ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... software and services, is proud to announce it has joined the National Association ... representing the interests of chronically ill, disabled, and dying Americans of all ages ...
(Date:3/28/2017)... ... March 28, 2017 , ... Alert Sentry Group LLC., ... (Mobile Personal Emergency Response Systems), the iSAFE and the iSAFE Plus. These iSAFE products ... first of their kind, the iSAFE and iSAFE Plus offer direct GPS Location and ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... March 29, 2017  NuVasive, Inc. (NASDAQ: NUVA), ... spine surgery with minimally disruptive, procedurally-integrated solutions, today ... clearance of the CoRoent® Small Interbody™ System indicated ... in the cervical spine. This marks the first ... used at up to four contiguous levels. ...
(Date:3/29/2017)... , March 29, 2017 NetworkNewsWire ... ... the public safety in regulating marijuana, but economic arguments also ... creation, and reduced law enforcement costs. However, to legalize and ... provided by SinglePoint, Inc. (OTC: SING) ( SING Profile ), ...
(Date:3/29/2017)... - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical ... ended December 31, 2016 after market close on ... released later than the previous fiscal year,s results ... and balances of Apicore from the acquisition date ... date meets TSX Venture Exchange listed company requirements. ...
Breaking Medicine Technology: